HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ceramides promote apoptosis for virus-infected lymphoma cells through induction of ceramide synthases and viral lytic gene expression.

Abstract
Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiologic agent for several human cancers including primary effusion lymphoma (PEL), a rapidly progressive malignancy arising preferentially in immunocompromised patients. With conventional chemotherapy, PEL continues to portend high mortality, dictating the development of novel therapeutic strategies. Sphingosine kinase 2 (SphK2) represents a key gatekeeper for sphingolipid metabolism, responsible for conversion of ceramides to sphingosine-1-phosphate (S1P). We have previously demonstrated that targeting SphK2 using a novel selective inhibitor, ABC294640, leads to intracellular accumulation of ceramides and induces apoptosis for KSHV-infected PEL cells, while suppressing tumor progression in vivo. In the current study, we sought to determine whether specific ceramide/dh-ceramide species and related ceramide synthases (CerS) impact viability for KSHV-infected PEL cells during targeting of SphK2. We found that several specific ceramide and dihydro(dh)-ceramide species and their associated CerS reduce PEL survival and tumor expansion in vitro and in vivo. Moreover, we found that dhC16-Cer induces PEL apoptosis in part through activation of KSHV lytic gene expression. These data further implicate bioactive sphingolipids in regulation of PEL survival, and provide justification for future studies evaluating clinically relevant ceramide analogs or mimetics for their potential as therapeutic agents for PEL.
AuthorsLu Dai, Jimena Trillo-Tinoco, Aiping Bai, Yihan Chen, Jacek Bielawski, Luis Del Valle, Charles D Smith, Augusto C Ochoa, Zhiqiang Qin, Chris Parsons
JournalOncotarget (Oncotarget) Vol. 6 Issue 27 Pg. 24246-60 (Sep 15 2015) ISSN: 1949-2553 [Electronic] United States
PMID26327294 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Antineoplastic Agents
  • Ceramides
  • Lysophospholipids
  • Pyridines
  • Sphingolipids
  • sphingosine 1-phosphate
  • 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
  • Oxidoreductases
  • dihydroceramide desaturase
  • Phosphotransferases (Alcohol Group Acceptor)
  • sphingosine kinase 2, human
  • Sphingosine
  • Adamantane
Topics
  • Adamantane (analogs & derivatives, chemistry)
  • Animals
  • Antineoplastic Agents (chemistry)
  • Apoptosis
  • Cell Survival
  • Ceramides (metabolism)
  • Gene Expression Regulation, Neoplastic
  • Gene Expression Regulation, Viral
  • Humans
  • Lymphoma, Primary Effusion (metabolism, virology)
  • Lysophospholipids (metabolism)
  • Male
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Neoplasm Transplantation
  • Oxidoreductases (metabolism)
  • Phosphotransferases (Alcohol Group Acceptor) (metabolism)
  • Pyridines (chemistry)
  • RNA Interference
  • Sphingolipids (metabolism)
  • Sphingosine (analogs & derivatives, metabolism)
  • Up-Regulation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: